Paion Ag Aachen (PAIOF) 2.3200 $PAIOF
PAION Grants Cosmo Pharmaceuticals remimazolam License in the U.S. and Cosmo Becomes Largest Shareholder of PAION AG
BusinessWire - Fri Jun 24, 1:12PM CDT
--- PAION entitled to receive up to EUR 42.5 million in milestone payments and significant double-digit tiered royalties
The Anesthetic Effect Pipeline Review, H2 2015 - 16 Companies & 24 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/25xt8p/anesthetic_effect) has announced the addition of the "Anesthetic Effect - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - (lidocaine hydrochloride phenylephrine hydrochloride tropicamide) - (tetracaine hydrochloride oxymetazoline hydrochloride) - ABP-700 - ADV-6209 - alphaxalone - bupivacaine hydrochloride - carboetomidate - Gabafol - HSK-3486 - lidocaine hydrochloride ER - LT-1121 - LT-1123 - methoxycarbonyl carboetomidate - methoxycarbonyl etomidate - neosaxitoxin - PB-5109 - PHY-301 - propofol - propofol microemulsion - propofol-DM - remimazolam - remimazolam - Small Molecules to Inhibit NMDA Receptor for Anaesthesia - sugammadex sodium Companies Mentioned - Advicenne Pharma - Biolab Sanus Farmaceutica Ltda. - Drawbridge Pharmaceuticals Pty Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Juniper Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Lipicard Technologies Limited - Merck & Co., Inc. - NanoMedex Pharmaceuticals, Inc. - Paion AG - Phosphagenics Limited - Physica Pharma SAS - Proteus SA - Sphaera Pharma Pvt. Ltd. - Taiwan Liposome Company, Ltd. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/25...tic_effect
MRK: 58.79 (+0.36), JNP: 7.60 (+0.08)
PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Marketwired - Tue Dec 01, 7:02AM CST
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a smaller dedicated safety study of Remimazolam in ASA III/IV patients (American Society of Anesthesiologists classification III to IV) undergoing colonoscopy as part of the U.S. Phase III program. This trial will run alongside the two ongoing pivotal U.S. Phase III trials in colonoscopy and bronchoscopy.
Remimazolam Posters at Anesthesiology(R) 2015
Marketwired - Mon Oct 12, 7:01AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG (XETRA: PA8), today announced its presence (booth 2315) and the presentation of results so far generated in the completed clinical trials in general anesthesia with Remimazolam at Anesthesiology® 2015.
Sedation - Pipeline Review, H2 2015
M2 - Fri Sep 04, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wn8rs9/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Advicenne Pharma - AstraZeneca Plc - Concert Pharmaceuticals - Drawbridge Pharmaceuticals - Jiangsu Nhwa Pharma Corporation - NanoMedex Pharmaceuticals - Paion AG - The Medicines Company For more information visit http://www.researchandmarkets.com/research/wn8rs9/sedation
AZN: 33.58 (-0.71), CNCE: 11.49 (-0.28)
Timothy E. Morris Joins PAION Inc. As A Non Executive Director
PR Newswire - Fri Aug 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the appointment of Timothy E. Morris to the non executive Board of PAION, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise PAION Inc. on the financing of the company's growing U.S. activities and in preparing for the upcoming commercialisation of Remimazolam.
PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
PR Newswire - Mon Jun 08, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of the second pivotal U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.
David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc
PR Newswire - Thu May 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
PAION Grants Cosmo Pharmaceuticals remimazolam License in the U.S. and Cosmo Becomes Largest Shareholder of PAION AG
BusinessWire - Fri Jun 24, 1:12PM CDT
--- PAION entitled to receive up to EUR 42.5 million in milestone payments and significant double-digit tiered royalties
The Anesthetic Effect Pipeline Review, H2 2015 - 16 Companies & 24 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/25xt8p/anesthetic_effect) has announced the addition of the "Anesthetic Effect - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - (lidocaine hydrochloride phenylephrine hydrochloride tropicamide) - (tetracaine hydrochloride oxymetazoline hydrochloride) - ABP-700 - ADV-6209 - alphaxalone - bupivacaine hydrochloride - carboetomidate - Gabafol - HSK-3486 - lidocaine hydrochloride ER - LT-1121 - LT-1123 - methoxycarbonyl carboetomidate - methoxycarbonyl etomidate - neosaxitoxin - PB-5109 - PHY-301 - propofol - propofol microemulsion - propofol-DM - remimazolam - remimazolam - Small Molecules to Inhibit NMDA Receptor for Anaesthesia - sugammadex sodium Companies Mentioned - Advicenne Pharma - Biolab Sanus Farmaceutica Ltda. - Drawbridge Pharmaceuticals Pty Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Juniper Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Lipicard Technologies Limited - Merck & Co., Inc. - NanoMedex Pharmaceuticals, Inc. - Paion AG - Phosphagenics Limited - Physica Pharma SAS - Proteus SA - Sphaera Pharma Pvt. Ltd. - Taiwan Liposome Company, Ltd. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/25...tic_effect
MRK: 58.79 (+0.36), JNP: 7.60 (+0.08)
PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Marketwired - Tue Dec 01, 7:02AM CST
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a smaller dedicated safety study of Remimazolam in ASA III/IV patients (American Society of Anesthesiologists classification III to IV) undergoing colonoscopy as part of the U.S. Phase III program. This trial will run alongside the two ongoing pivotal U.S. Phase III trials in colonoscopy and bronchoscopy.
Remimazolam Posters at Anesthesiology(R) 2015
Marketwired - Mon Oct 12, 7:01AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG (XETRA: PA8), today announced its presence (booth 2315) and the presentation of results so far generated in the completed clinical trials in general anesthesia with Remimazolam at Anesthesiology® 2015.
Sedation - Pipeline Review, H2 2015
M2 - Fri Sep 04, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wn8rs9/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Advicenne Pharma - AstraZeneca Plc - Concert Pharmaceuticals - Drawbridge Pharmaceuticals - Jiangsu Nhwa Pharma Corporation - NanoMedex Pharmaceuticals - Paion AG - The Medicines Company For more information visit http://www.researchandmarkets.com/research/wn8rs9/sedation
AZN: 33.58 (-0.71), CNCE: 11.49 (-0.28)
Timothy E. Morris Joins PAION Inc. As A Non Executive Director
PR Newswire - Fri Aug 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the appointment of Timothy E. Morris to the non executive Board of PAION, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise PAION Inc. on the financing of the company's growing U.S. activities and in preparing for the upcoming commercialisation of Remimazolam.
PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
PR Newswire - Mon Jun 08, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of the second pivotal U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.
David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc
PR Newswire - Thu May 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
